NeoGenomics expects 3Q revenue of about $209 million, with next-generation sequencing revenue up roughly 28% year over year. The company says the preliminary figure is expected to lead to an increase in full-year revenue guidance at the midpoint, with details to come on the earnings call. The company also reiterated its full-year adjusted Ebitda guidance. NeoGenomics announced its guidance as the oncology diagnostic company named Warren Stone as incoming CEO.

This article was automatically created using artificial-intelligence technology and reviewed by Dow Jones Newswires editors.